Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Aptamer Group and AstraZeneca to develop new drug delivery vehicles

Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney.

From AstraZeneca 10 Jan 2019

Drug development options diversified with new manganese catalyst

A University of Illinois team of researchers led by chemistry professor M. Christina White has developed a new manganese-based catalyst that can change the structure of druglike molecules to make new drugs, advancing the pace and efficiency of drug development.

9 Jan 2019

TARA Biosystems and Insilico Medicine collaborate to discover novel therapies for cardiac disease

TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and risk assessment applications and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop novel therapies for cardiac disease and diseases associated with cardiac muscle aging.

9 Jan 2019

CytoReason enters into drug discovery collaboration agreement with Pfizer

CytoReason, a leader in machine learning for drug discovery and development, announced today that it has entered into a collaboration agreement with Pfizer Inc. that will leverage CytoReason's cell-centered models of the immune system.

8 Jan 2019

Insilico Medicine and TARA Biosystems collaborate to develop novel therapies for cardiac diseases

Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases and TARA Biosystems, Inc. a company offering "heart-on-a-chip" tissue models for drug discovery and risk assessment applications, announced today the launch of a collaboration to discover and develop novel therapies for cardiac disease and diseases associated with cardiac muscle aging.

8 Jan 2019

USC research could lay foundation for a vaccine against tick-borne virus

Two groundbreaking discoveries by USC researchers could lead to medications and a vaccine to treat or prevent a hemorrhagic fever transmitted by a new tick species before it spreads across the United States.

7 Jan 2019

New medications provide better treatment for alcohol use disorders, chronic pain, mood disorders

Helping people with addictions has become a research passion for Purdue University's Richard van Rijn, who is leading a team to make drug discoveries to support millions around the world dealing with alcohol use disorders, chronic pain and mood disorders.

3 Jan 2019

New book series on anti-obesity treatment strategies

Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses.

2 Jan 2019

Insilico to present 'AI-powered end-to-end pipelines for drug discovery' at Longevity Therapeutics 2019

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at The Longevity Therapeutics 2019 in San Francisco, 30 of January.

30 Dec 2018

Targeting thymidylate biosynthesis in kinetoplastid and apicomplexan protozoans

Kinetoplastid and apicomplexan parasites include protozoans which are responsible for human diseases, and cause a serious impact on human health and the socioeconomic growth of developing countries. Chemotherapy is the main option to control these pathogenic organisms.

27 Dec 2018

Lupin partners with Abbvie to develop and commercialize new targeted oncology treatments

Pharma major Lupin Limited and global biopharmaceutical company AbbVie Inc., today announced that AbbVie has licensed Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.

25 Dec 2018

Researchers synthesize new compound that inhibits replication of hepatitis C virus

A new compound that inhibits the replication of hepatitis C virus in several stages of its lifecycle - and is also capable of acting on bacteria, fungi and cancer cells - has been synthesized by researchers at São Paulo State University in Brazil.

19 Dec 2018

Horizon Discovery partners with C4XD to validate novel synthetic lethal oncology targets

Horizon Discovery Group today announces that it has entered into an exclusive target discovery partnership with C4XD, a pioneering drug discovery company.

From Revvity 19 Dec 2018

Researchers discover promising new compound against Buruli ulcer

Buruli ulcer - one of the most neglected among the NTDs - is a debilitating and stigmatizing disease. Affecting mainly children in West and Central Africa, the chronic disease results in devastating skin lesions and can lead to permanent disfigurement and long-term disabilities.

18 Dec 2018

New compound blocks genetic cause of familial ALS and frontotemporal dementia

Since the ice bucket challenge went viral in 2014, raising awareness and funding for ALS research, scientists have learned much about a disease that disconnects muscles from nerves, leading to muscle atrophy and eventual death. Their ultimate goal is to create medications capable of stopping ALS in its tracks.

18 Dec 2018

Drug Discovery News and Research

Further Reading

Aptamer Group and AstraZeneca to develop new drug delivery vehicles

Drug development options diversified with new manganese catalyst

TARA Biosystems and Insilico Medicine collaborate to discover novel therapies for cardiac disease

CytoReason enters into drug discovery collaboration agreement with Pfizer

Insilico Medicine and TARA Biosystems collaborate to develop novel therapies for cardiac diseases

USC research could lay foundation for a vaccine against tick-borne virus

New medications provide better treatment for alcohol use disorders, chronic pain, mood disorders

New book series on anti-obesity treatment strategies

Insilico to present 'AI-powered end-to-end pipelines for drug discovery' at Longevity Therapeutics 2019

Targeting thymidylate biosynthesis in kinetoplastid and apicomplexan protozoans

Lupin partners with Abbvie to develop and commercialize new targeted oncology treatments

Researchers synthesize new compound that inhibits replication of hepatitis C virus

Horizon Discovery partners with C4XD to validate novel synthetic lethal oncology targets

Researchers discover promising new compound against Buruli ulcer

New compound blocks genetic cause of familial ALS and frontotemporal dementia

Getting the Most Out of the CLARITY Technique

World's largest AI-powered medical research network launched by OWKIN

Allen Institute for Immunology: A new division focused on human immune system

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

New collaborative partnership in quest of novel antibiotics

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News